Trial Outcomes & Findings for Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study (NCT NCT04926233)
NCT ID: NCT04926233
Last Updated: 2021-11-15
Results Overview
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Recruitment status
COMPLETED
Target enrollment
1371146 participants
Primary outcome timeframe
At index date of cohort entry (baseline; time of COPD diagnosis).
Results posted on
2021-11-15
Participant Flow
This retrospective cohort study used previously collected administrative healthcare data (United States data from IBM MarketScan and United Kingdom data from CPRD GOLD, a primary care database) to describe the patients characteristics and treatment patterns in patients with chronic obstructive pulmonary disease (COPD), initiating tiotropium + olodaterol or other maintenance therapies.
Patients with chronic obstructive pulmonary disease (COPD) who met all inclusion criteria and none of the exclusion criteria initiating tiotropium + olodaterol or other maintenance therapies from either IBM MarketScan (United States) or CPRD GOLD (United Kingdom) databases were included.
Participant milestones
| Measure |
US IBM Marketscan - Overall
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
|
UK CPRD GOLD - Overall
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
|---|---|---|
|
Overall Study
STARTED
|
1280486
|
90660
|
|
Overall Study
COMPLETED
|
1280486
|
90660
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
US IBM Marketscan - Overall
n=1280486 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
|
UK CPRD GOLD - Overall
n=90660 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
Total
n=1371146 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
65.3 Years
STANDARD_DEVIATION 13.2 • n=1280486 Participants
|
65.9 Years
STANDARD_DEVIATION 13.5 • n=90660 Participants
|
65.3 Years
STANDARD_DEVIATION 13.2 • n=1371146 Participants
|
|
Sex: Female, Male
Female
|
649296 Participants
n=1280486 Participants
|
46923 Participants
n=90660 Participants
|
696219 Participants
n=1371146 Participants
|
|
Sex: Female, Male
Male
|
631190 Participants
n=1280486 Participants
|
43737 Participants
n=90660 Participants
|
674927 Participants
n=1371146 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: At index date of cohort entry (baseline; time of COPD diagnosis).Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=1021963 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=258523 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US
|
65.6 Years
Standard Deviation 13.3
|
64.4 Years
Standard Deviation 12.8
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: At index date of cohort entry (baseline; time of COPD diagnosis).Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=79412 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=11248 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK
|
65.82 Years
Standard Deviation 13.81
|
66.17 Years
Standard Deviation 11.17
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: At index date of cohort entry (baseline; time of COPD diagnosis).Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018). Results were reported by overall and by stratified groups according to Tiotropium + Olodaterol approval date for US and UK datasets, respectively.
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=1280486 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=1021963 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=258523 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=90660 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=79412 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=11248 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis
|
1.6 Score on a scale
Standard Deviation 1.9
|
1.5 Score on a scale
Standard Deviation 1.9
|
1.9 Score on a scale
Standard Deviation 2.1
|
1.89 Score on a scale
Standard Deviation 1.38
|
1.83 Score on a scale
Standard Deviation 1.32
|
2.31 Score on a scale
Standard Deviation 1.66
|
—
|
—
|
PRIMARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=53473 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=6737 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=351 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=26378 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=6745 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=2237 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=10892 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=133 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of Patients Receiving First Maintenance Treatment - US
|
63.0 Years
Interval 57.0 to 73.0
|
62.0 Years
Interval 56.0 to 73.0
|
67.0 Years
Interval 59.0 to 79.0
|
62.0 Years
Interval 56.0 to 72.0
|
62.0 Years
Interval 56.0 to 72.0
|
63.0 Years
Interval 58.0 to 74.0
|
64.0 Years
Interval 58.0 to 75.0
|
65.0 Years
Interval 58.0 to 76.0
|
PRIMARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=53473 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=6737 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=351 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=26378 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=6745 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=2237 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=10892 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=133 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 5.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 3.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
PRIMARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=53473 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=6737 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=351 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=26378 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=6745 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=2237 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=10892 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=133 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Upper respiratory tract infection
|
13803 Participants
|
2114 Participants
|
87 Participants
|
7151 Participants
|
1632 Participants
|
486 Participants
|
2299 Participants
|
34 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Lower respiratory tract infection
|
8525 Participants
|
1160 Participants
|
46 Participants
|
4577 Participants
|
885 Participants
|
367 Participants
|
1474 Participants
|
16 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Pneumonia
|
9946 Participants
|
1253 Participants
|
77 Participants
|
4762 Participants
|
1014 Participants
|
651 Participants
|
2160 Participants
|
29 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Chronic bronchitis
|
5161 Participants
|
603 Participants
|
42 Participants
|
2642 Participants
|
502 Participants
|
294 Participants
|
1066 Participants
|
12 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Lung fibrosis
|
1868 Participants
|
239 Participants
|
22 Participants
|
882 Participants
|
207 Participants
|
108 Participants
|
405 Participants
|
5 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Concomitant medications - Oral corticosteroids
|
23272 Participants
|
3172 Participants
|
152 Participants
|
12240 Participants
|
2770 Participants
|
929 Participants
|
3959 Participants
|
50 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Concomitant medications - Oral antibiotics
|
37829 Participants
|
5047 Participants
|
249 Participants
|
19168 Participants
|
4645 Participants
|
1508 Participants
|
7116 Participants
|
96 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - US
Concomitant medications - Oxygen therapy
|
4580 Participants
|
425 Participants
|
57 Participants
|
2094 Participants
|
625 Participants
|
305 Participants
|
1058 Participants
|
16 Participants
|
PRIMARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=8786 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=753 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=382 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1202 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1407 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=352 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=4675 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=15 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of Patients Receiving First Maintenance Treatment - UK
|
68.0 Years
Interval 60.0 to 75.0
|
67.0 Years
Interval 59.0 to 75.0
|
67.0 Years
Interval 59.0 to 75.0
|
67.0 Years
Interval 59.0 to 75.0
|
68.0 Years
Interval 61.0 to 75.0
|
70.0 Years
Interval 62.0 to 77.0
|
68.0 Years
Interval 60.0 to 75.0
|
69.0 Years
Interval 64.0 to 73.0
|
PRIMARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=8786 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=753 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=382 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1202 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1407 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=352 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=4675 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=15 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Characteristics of Patients Receiving First Maintenance Treatment - UK
Upper respiratory tract infection
|
3802 Participants
|
454 Participants
|
166 Participants
|
545 Participants
|
541 Participants
|
143 Participants
|
1946 Participants
|
7 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - UK
Lower respiratory tract infection (not pneumonia)
|
4835 Participants
|
501 Participants
|
220 Participants
|
721 Participants
|
732 Participants
|
164 Participants
|
2486 Participants
|
11 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - UK
Concomitant medications - Oral corticosteroids
|
2367 Participants
|
207 Participants
|
87 Participants
|
453 Participants
|
353 Participants
|
121 Participants
|
1140 Participants
|
6 Participants
|
|
Characteristics of Patients Receiving First Maintenance Treatment - UK
Concomitant medications - Oral antibiotics
|
5133 Participants
|
480 Participants
|
204 Participants
|
796 Participants
|
797 Participants
|
224 Participants
|
2624 Participants
|
8 Participants
|
PRIMARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=7028 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=584 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=82 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1813 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1125 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=1834 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=1450 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=140 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of Patients Receiving Second Maintenance Treatment - US
|
64.0 Years
Interval 58.0 to 74.0
|
63.0 Years
Interval 57.0 to 74.0
|
70.0 Years
Interval 62.0 to 79.0
|
63.0 Years
Interval 58.0 to 73.0
|
63.0 Years
Interval 58.0 to 73.0
|
64.0 Years
Interval 58.0 to 73.0
|
64.0 Years
Interval 59.0 to 75.0
|
65.0 Years
Interval 60.0 to 78.5
|
PRIMARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=7028 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=584 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=82 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1813 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1125 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=1834 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=1450 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=140 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 2.0 to 4.0
|
3.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 4.0
|
3.0 Score on a scale
Interval 2.0 to 4.0
|
2.0 Score on a scale
Interval 1.0 to 5.0
|
PRIMARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=7028 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=584 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=82 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1813 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1125 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=1834 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=1450 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=140 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Lung fibrosis
|
388 Participants
|
37 Participants
|
11 Participants
|
101 Participants
|
43 Participants
|
105 Participants
|
79 Participants
|
12 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Male
|
3674 Participants
|
265 Participants
|
41 Participants
|
920 Participants
|
628 Participants
|
998 Participants
|
749 Participants
|
73 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Upper respiratory tract infection
|
1842 Participants
|
196 Participants
|
25 Participants
|
497 Participants
|
307 Participants
|
442 Participants
|
343 Participants
|
32 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Lower respiratory infections
|
1385 Participants
|
130 Participants
|
13 Participants
|
368 Participants
|
213 Participants
|
372 Participants
|
260 Participants
|
29 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Chronic bronchitis
|
1095 Participants
|
89 Participants
|
11 Participants
|
264 Participants
|
165 Participants
|
297 Participants
|
243 Participants
|
26 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Concomitant medications - Oral corticosteroids
|
4065 Participants
|
355 Participants
|
44 Participants
|
1019 Participants
|
595 Participants
|
1125 Participants
|
851 Participants
|
75 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - US
Concomitant medications - Oral antibiotics
|
5399 Participants
|
481 Participants
|
64 Participants
|
1399 Participants
|
833 Participants
|
1388 Participants
|
1126 Participants
|
108 Participants
|
PRIMARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=2461 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=60 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=101 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=338 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=970 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=685 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=222 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=85 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Age of Patients Receiving Second Maintenance Treatment - UK
|
68.0 Years
Interval 61.0 to 75.0
|
68.0 Years
Interval 61.5 to 74.0
|
71.0 Years
Interval 63.0 to 76.0
|
69.0 Years
Interval 61.0 to 77.0
|
68.0 Years
Interval 61.0 to 74.0
|
68.0 Years
Interval 60.0 to 74.0
|
70.0 Years
Interval 62.0 to 77.0
|
68.0 Years
Interval 59.0 to 73.0
|
PRIMARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=2461 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=60 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=101 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=338 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=970 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=685 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=222 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=85 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Characteristics of Patients Receiving Second Maintenance Treatment - UK
Male
|
1375 Participants
|
31 Participants
|
51 Participants
|
191 Participants
|
555 Participants
|
383 Participants
|
127 Participants
|
37 Participants
|
|
Characteristics of Patients Receiving Second Maintenance Treatment - UK
Concomitant medications - Oral corticosteroids
|
1066 Participants
|
25 Participants
|
36 Participants
|
152 Participants
|
356 Participants
|
385 Participants
|
71 Participants
|
41 Participants
|
SECONDARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=53473 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=6737 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=351 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=26378 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=6745 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=2237 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=10892 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=133 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US
|
26242 Participants
|
3518 Participants
|
183 Participants
|
12483 Participants
|
3818 Participants
|
676 Participants
|
5515 Participants
|
49 Participants
|
SECONDARY outcome
Timeframe: At index date of the first maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=8786 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=753 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=382 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1202 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1407 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=352 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=4675 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=15 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK
|
5942 Participants
|
498 Participants
|
275 Participants
|
712 Participants
|
960 Participants
|
207 Participants
|
3281 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=7028 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=584 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=82 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1813 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1125 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=1834 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=1450 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=140 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US
|
2361 Participants
|
226 Participants
|
29 Participants
|
684 Participants
|
426 Participants
|
505 Participants
|
451 Participants
|
40 Participants
|
SECONDARY outcome
Timeframe: At index date of the second maintenance treatmentPopulation: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=2461 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=60 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=101 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=338 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=970 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=685 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=222 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=85 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK
|
1351 Participants
|
34 Participants
|
63 Participants
|
172 Participants
|
590 Participants
|
299 Participants
|
144 Participants
|
49 Participants
|
SECONDARY outcome
Timeframe: From index date until initiation of first maintenance, up to 3368 days before this study started.Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=53473 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=6737 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=351 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=26378 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=6745 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=2237 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=10892 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=133 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Days Between Index and Initiation of First Maintenance Therapy - US
|
158.0 Days
Interval 12.0 to 839.0
|
242.0 Days
Interval 17.0 to 972.0
|
233.0 Days
Interval 14.0 to 902.0
|
165.0 Days
Interval 12.0 to 833.0
|
116.0 Days
Interval 15.0 to 672.0
|
78.0 Days
Interval 7.0 to 770.0
|
136.0 Days
Interval 9.0 to 879.0
|
85.0 Days
Interval 6.0 to 957.0
|
SECONDARY outcome
Timeframe: From index date until initiation of first maintenance therapy, up to 9795 days before this study started.Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies.
Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=8786 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=753 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=382 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1202 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1407 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=352 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=4675 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=15 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Days Between Index and Initiation of First Maintenance Therapy - UK
|
28.5 Days
Interval 1.0 to 521.0
|
708.0 Days
Interval 43.0 to 3145.0
|
43.5 Days
Interval 1.0 to 555.0
|
32.0 Days
Interval 1.0 to 566.0
|
19.0 Days
Interval 1.0 to 368.0
|
19.0 Days
Interval 1.0 to 141.5
|
22.0 Days
Interval 1.0 to 376.0
|
19.0 Days
Interval 1.0 to 123.0
|
SECONDARY outcome
Timeframe: From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started.Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=7028 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=584 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=82 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=1813 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=1125 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=1834 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=1450 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=140 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Days Between First and Second Maintenance Therapy - US
|
160.0 Days
Interval 76.0 to 335.0
|
181.5 Days
Interval 89.5 to 339.5
|
176.0 Days
Interval 86.0 to 282.0
|
158.0 Days
Interval 74.0 to 321.0
|
223.0 Days
Interval 100.0 to 415.0
|
143.5 Days
Interval 70.0 to 314.0
|
137.0 Days
Interval 66.0 to 301.0
|
125.0 Days
Interval 67.0 to 266.5
|
SECONDARY outcome
Timeframe: From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started.Population: All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies.
Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported.
Outcome measures
| Measure |
US IBM Marketscan - COPD Diagnosis Before Tio+Olo Approval
n=2461 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=60 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval
n=101 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group.
|
UK CPRD GOLD - Overall
n=338 Participants
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
|
UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval
n=970 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval
n=685 Participants
Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018).
Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group.
|
US IBM Marketscan - 1MT - LAMA
n=222 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group.
|
US IBM Marketscan - 1MT - LAMA+ICS
n=85 Participants
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma.
Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group
|
|---|---|---|---|---|---|---|---|---|
|
Days Between First and Second Maintenance Therapy - UK
|
218.0 Days
Interval 86.0 to 428.0
|
239.5 Days
Interval 61.5 to 528.0
|
141.0 Days
Interval 74.0 to 412.0
|
155.5 Days
Interval 67.0 to 335.0
|
284.0 Days
Interval 113.0 to 483.0
|
197.0 Days
Interval 82.0 to 397.0
|
225.5 Days
Interval 96.0 to 415.0
|
158.0 Days
Interval 71.0 to 281.0
|
Adverse Events
US IBM Marketscan - Overall
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
UK CPRD GOLD - Overall
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Boehringer Ingelheim Call Center
Boehringer Ingelheim
Phone: 1-800-243-0127
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER